[Federal Register Volume 85, Number 123 (Thursday, June 25, 2020)]
[Notices]
[Page 38147]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-13656]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. to achieve 
expeditious commercialization of results of federally-funded research 
and development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing Michael Shmilovich, [email protected], the indicated 
licensing contact at the National Heart, Lung, and Blood, Office of 
Technology Transfer and Development Office of Technology Transfer, 31 
Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 
301-402-5579. A signed Confidential Disclosure Agreement may be 
required to receive any unpublished information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Liposome Nanodecoys That Protect Against SARS-COV-2

    Available for licensing and commercial development are patent 
rights covering a liposomal vesicle (a ``nanodecoy'') with a lipid 
bilayer with one or more proteins recognized by a pathogen (e.g., SARS-
CoV-2) and one or more cytokine receptors (such as IL-6; receptors: 
CD126, CD130; IL-1; receptors: CD121a, CD121b, IL-8; receptors: IL-8RB; 
IL-12; receptors: CD212; TNF-[alpha]; receptors: CD120a, CD120b; IFN-
[gamma]; receptors: CD119, IFN-[alpha]/[beta]; receptors: CD118) and 
wherein the liposomal vesicle is non-replicating. Nanodecoys that 
display angiotensin-converting enzyme 2 (ACE2) and multiple cytokine 
receptors, are able to sequester SARS-CoV-2 and inhibit viral 
replication and infection, as well as to mitigate COVID-19-induced 
cytokine release syndrome (CRS) in susceptible cells.
    Potential Commercial Applications:

 COVID-19
 SARS-CoV-2
 Cytokine release syndrome
    [cir] immunosuppression
 Viral inhibition
    [cir] Receptor binding competition

    Development Stage:

 Preclinical

    Inventors: Xiaoyuan (Shawn) Chen (NIBIB) and Lang Rao (NIBIB).
    Intellectual Property: HHS Reference No. E-144-2020-0-US-01 
``Engineered Cell Membrane Nanodecoys To Protect Against COVID-19;'' 
U.S. Provisional Patent Application 63/038,380 filed June 12, 2020.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: June 17, 2020.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2020-13656 Filed 6-24-20; 8:45 am]
BILLING CODE 4140-01-P